September 21, 2021 - … and industry-leading pipeline including Phase 3 lecanemab Potential to transform standard of care in several … addition to ADUHELM, the company will present progress on lecanemab (BAN2401), a new amyloid beta-directed antibody … a tau-directed antisense oligonucleotide (ASO). Lecanemab received Breakthrough Therapy designation from the …